GlaxoSmithKline PLC (GSK) - Total Liabilities
Based on the latest financial reports, GlaxoSmithKline PLC (GSK) has total liabilities worth GBX45.59 Billion GBX (≈ $5.55 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of GlaxoSmithKline PLC to see how much of total assets are deployed in long-term investments.
GlaxoSmithKline PLC - Total Liabilities Trend (1986–2024)
This chart illustrates how GlaxoSmithKline PLC's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see GSK current and non-current assets.
GlaxoSmithKline PLC Competitors by Total Liabilities
The table below lists competitors of GlaxoSmithKline PLC ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Shanghai Anoky Group
SHE:300067
|
China | CN¥1.03 Billion |
|
CH. Karnchang PCL
BK:CK
|
Thailand | ฿87.98 Billion |
|
Guararapes Confecções S.A
SA:GUAR3
|
Brazil | R$9.52 Billion |
|
Aebi Schmidt Holding AG - Common Stock
NASDAQ:AEBI
|
USA | $1.48 Billion |
|
Dios Fastigheter AB
ST:DIOS
|
Sweden | Skr21.52 Billion |
|
CeriBell, Inc
NASDAQ:CBLL
|
USA | $38.03 Million |
|
Cresud SA
BA:CRES
|
Argentina | AR$3.71 Trillion |
|
Oil-Dri Corporation Of America
NYSE:ODC
|
USA | $123.56 Million |
Liability Composition Analysis (1986–2024)
This chart breaks down GlaxoSmithKline PLC's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See debt-free asset ratio of GlaxoSmithKline PLC to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.84 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 2.82 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.74 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how GlaxoSmithKline PLC's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for GlaxoSmithKline PLC (1986–2024)
The table below shows the annual total liabilities of GlaxoSmithKline PLC from 1986 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | GBX46.38 Billion ≈ $5.64 Million |
+0.36% |
| 2023-12-31 | GBX46.21 Billion ≈ $5.62 Million |
-7.67% |
| 2022-12-31 | GBX50.05 Billion ≈ $6.09 Million |
-13.35% |
| 2021-12-31 | GBX57.76 Billion ≈ $7.03 Million |
-3.12% |
| 2020-12-31 | GBX59.62 Billion ≈ $7.25 Million |
-2.79% |
| 2019-12-31 | GBX61.34 Billion ≈ $7.46 Million |
+12.76% |
| 2018-12-31 | GBX54.39 Billion ≈ $6.62 Million |
+2.84% |
| 2017-12-31 | GBX52.89 Billion ≈ $6.44 Million |
-2.27% |
| 2016-12-31 | GBX54.12 Billion ≈ $6.58 Million |
+21.43% |
| 2015-12-31 | GBX44.57 Billion ≈ $5.42 Million |
+24.79% |
| 2014-12-31 | GBX35.72 Billion ≈ $4.35 Million |
+4.20% |
| 2013-12-31 | GBX34.27 Billion ≈ $4.17 Million |
-1.31% |
| 2012-12-31 | GBX34.73 Billion ≈ $4.23 Million |
+7.67% |
| 2011-12-31 | GBX32.25 Billion ≈ $3.92 Million |
-0.17% |
| 2010-12-31 | GBX32.31 Billion ≈ $3.93 Million |
+0.58% |
| 2009-12-31 | GBX32.12 Billion ≈ $3.91 Million |
+3.36% |
| 2008-12-31 | GBX31.07 Billion ≈ $3.78 Million |
+47.32% |
| 2007-12-31 | GBX21.09 Billion ≈ $2.57 Million |
+32.62% |
| 2006-12-31 | GBX15.90 Billion ≈ $1.94 Million |
-18.97% |
| 2005-12-31 | GBX19.63 Billion ≈ $2.39 Million |
+15.41% |
| 2004-12-31 | GBX17.01 Billion ≈ $2.07 Million |
+10.46% |
| 2003-12-31 | GBX15.40 Billion ≈ $1.87 Million |
+3.06% |
| 2002-12-31 | GBX14.94 Billion ≈ $1.82 Million |
+10.10% |
| 2001-12-31 | GBX13.57 Billion ≈ $1.65 Million |
+7.39% |
| 2000-12-31 | GBX12.63 Billion ≈ $1.54 Million |
+74.66% |
| 1999-12-31 | GBX7.23 Billion ≈ $880.17K |
+9.97% |
| 1998-12-31 | GBX6.58 Billion ≈ $800.35K |
+0.47% |
| 1997-12-31 | GBX6.55 Billion ≈ $796.58K |
-7.10% |
| 1996-12-31 | GBX7.05 Billion ≈ $857.42K |
-15.30% |
| 1995-12-31 | GBX8.32 Billion ≈ $1.01 Million |
+10.53% |
| 1995-06-30 | GBX7.53 Billion ≈ $915.87K |
+174.92% |
| 1994-06-30 | GBX2.74 Billion ≈ $333.14K |
-2.25% |
| 1993-06-30 | GBX2.80 Billion ≈ $340.80K |
+37.10% |
| 1992-06-30 | GBX2.04 Billion ≈ $248.57K |
-17.02% |
| 1991-06-30 | GBX2.46 Billion ≈ $299.55K |
+45.94% |
| 1990-06-30 | GBX1.69 Billion ≈ $205.26K |
+45.93% |
| 1989-06-30 | GBX1.16 Billion ≈ $140.65K |
+8.65% |
| 1988-06-30 | GBX1.06 Billion ≈ $129.46K |
+19.02% |
| 1987-06-30 | GBX894.00 Million ≈ $108.77K |
+27.17% |
| 1986-06-30 | GBX703.00 Million ≈ $85.53K |
-- |
About GlaxoSmithKline PLC
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, specialty medicines, and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through Commercial Operations and Total R&D segments. The company offers specialty medicines that include oncology, respiratory/immunology, infl… Read more